Enriqueta Felip

Enriqueta Felip

UNVERIFIED PROFILE

Are you Enriqueta Felip?   Register this Author

Register author
Enriqueta Felip

Enriqueta Felip

Publications by authors named "Enriqueta Felip"

Are you Enriqueta Felip?   Register this Author

100Publications

6842Reads

9Profile Views

Clinical Management of Adverse Events Associated with Lorlatinib.

Oncologist 2019 Aug 19;24(8):1103-1110. Epub 2019 Mar 19.

Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693708PMC
August 2019

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.

Cancer Immunol Immunother 2019 Mar 6;68(3):341-352. Epub 2019 Feb 6.

Lung Cancer Unit, Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02310-2
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02310-2DOI Listing
March 2019

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 11 29;36(31):3101-3109. Epub 2018 Aug 29.

Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Li Zhang, Sun Yat-sen University Cancer Center, Guangdong; Xiaoqing Liu, Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing; Sylvia Zhao and Bin Peng, Novartis Institutes for Biomedical Research, Shanghai, People's Republic of China; Dong-Wan Kim, Seoul National University Hospital; Dae Ho Lee, University of Ulsan College of Medicine; Myung-Ju Ahn, Samsung Medical Center, Seoul, Republic of Korea; James Chih-Hsin Yang, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Johan F. Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Vincent Chia and Philippe Pultar, Novartis Pharmaceuticals, East Hanover, NJ; Sabine Glaser and Mikhail Akimov, Novartis Pharma AG, Basel, Switzerland; and Daniel S.W. Tan, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.7326DOI Listing
November 2018

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J Med 2018 11 25;379(21):2027-2039. Epub 2018 Sep 25.

From the University of Colorado Cancer Center, Aurora (D.R.C.); Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine (H.R.K.), Samsung Medical Center (M.-J.A.), and Seoul National University Hospital (D.-W.K.), Seoul, National Cancer Center, Goyang (J.-Y.H.), Seoul National University Bundang Hospital, Seongnam (J.-S.L.), and Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.) - all in South Korea; National Taiwan University Hospital (J.C.-H.Y.) and the Faculty of Medicine, School of Medicine, National Yang-Ming University (G.-C.C.), Taipei, and the Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung (G.-C.C.) - all in Taiwan; the Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Department of Respiratory and Critical Care Medicine, Otto Wagner Hospital, Vienna (M.J.H.); Queen Elizabeth Hospital, Kowloon, Hong Kong (J.Y.-C.L.); Azienda Ospedaliera S. Giuseppe Moscati, Avellino (C.G.), the Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola (A.D.), Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS Struttura Operativa Complessa Oncologia Medica A, Aviano (A.B.), Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples (A.M.), and the Medical Oncology Unit, University Hospital of Parma, Parma (M.T.) - all in Italy; Complejo Hospitalario Universitario de A Coruña, Coruña (R.G.C.), and Vall d'Hebron University Hospital, Barcelona (E.F.) - both in Spain; the Department of Hematology and Oncology, University Department of Internal Medicine-Oncology, Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, Germany (F.G.); the Department of Medical Oncology, Christie NHS Foundation Trust, and Division of Cancer Sciences, University of Manchester, Manchester (R.C.), and Guy's and St. Thomas' NHS Foundation Trust (S.G.) and Royal Marsden Hospital and the National Heart and Lung Institute, Imperial College London (S.P.), London - all in the United Kingdom; Virginia Cancer Specialists Research Institute and US Oncology Research, The Woodlands, TX (A.S.); Yale Cancer Center, New Haven, CT (S.N.G.); and Millennium Pharmaceuticals, Cambridge, MA (N.G., J.H., D.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1810171DOI Listing
November 2018

COX-2 inhibitors in NSCLC: never-ending story or misplaced?

Transl Lung Cancer Res 2018 Sep;7(Suppl 3):S191-S194

Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2018.04.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193903PMC
September 2018

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 08 16;36(22):2251-2258. Epub 2018 May 16.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Tony S. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Osaka, Japan; Tarek Mekhail, Florida Hospital, Orlando, FL; Enriqueta Felip, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Federico Cappuzzo, Azienda Unità Sanitaria Locale Della Romagna, Ravenna; Jolanda Paolini and Tiziana Usari, Pfizer Oncology, Milan, Italy; Yiyun Tang and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; and Fiona Blackhall, Manchester University, and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.4794DOI Listing
August 2018

HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?

J Thorac Oncol 2018 07;13(7):874-876

Medical Oncology Department, Vall d'Hebron Hospital, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183060
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.05.005DOI Listing
July 2018

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

N Engl J Med 2018 May 16;378(22):2078-2092. Epub 2018 Apr 16.

From NYU Perlmutter Cancer Center, New York (L.G.); Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria (D.R.-A.), Hospital Universitario Central de Asturias, Oviedo (E.E.), Vall d'Hebron University, Vall d'Hebron Institute of Oncology, Barcelona (E.F.), and Fundación Jiménez Díaz (M.D.) and Hospital Universitario Quirón Madrid (B.R.-V.), Madrid - all in Spain; Karmanos Cancer Institute, Detroit (S.G.); Integrated Health and Social Services Centres, Montérégie Centre, Greenfield Park, QC (F.D.A.), and Sunnybrook Health Sciences Centre, Toronto (S.Y.-S.C.) - both in Canada; Southern Medical Day Care Centre, Wollongong, NSW (P.C.), Epworth Healthcare, Richmond, VIC (R.R.J.), Westmead Hospital and University of Sydney, Sydney (R.H.), and Chris O'Brien Lifehouse, Camperdown, NSW (M.B.) - all in Australia; Otto Wagner Hospital, Vienna (M.J.H.); Sanford Health, Sioux Falls, SD (S.F.P.); Thoraxklinik, Heidelberg (H.G.B.), and LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.) - both in Germany; Davidoff Cancer Center, Tel Aviv University, Petah Tikva, Israel (N.P.); Ospedale Policlinico San Martino, Genoa (F.G.), University of Turin, Azienda Ospedaliero-Universitaria San Luigi, Orbassano (S.N.), and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (M.C.G.) - all in Italy; David Geffen School of Medicine at UCLA, Los Angeles (E.B.G.); Kansai Medical University Hospital, Osaka, Japan (T.K.); Moffitt Cancer Center, Tampa, FL (J.E.G.); and Merck, Kenilworth, NJ (J.V., Z.W., J.Y., H.R., M.C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1801005DOI Listing
May 2018

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

J Clin Oncol 2017 Dec 12;35(35):3924-3933. Epub 2017 Oct 12.

Leora Horn, Vanderbilt-Ingram Cancer Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Everett E. Vokes, University of Chicago, Chicago, IL; Esther Holgado, Hospital De Madrid, Norte Sanchinarro, Madrid; Enriqueta Felip, Hospital Universitari Vall d'Hebron, Barcelona; Luis Paz-Ares, Hospital Universitario Virgen Del Rocio, Seville, Spain; Neal Ready, Duke University Medical Center, Durham, NC; Martin Steins, Thoraxklinik-Heidelberg gGmbH, Heidelberg; Martin Kohlhäeufl, Robert-Bosch-Krankenhaus, Stuttgart; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Wilfried E.E. Eberhardt, University Hospital and Ruhrlandclinic, University of Duisburg-Essen, Essen, Germany; Elena Poddubskaya, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Adam Pluzanski, Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie, Warsaw, Poland; Karen L. Reckamp, City of Hope, Duarte, CA; Marco A. Burgio and Lucio Crinò, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico Romagnolo Per lo Studio e la Cura dei Tumori, Meldola, Italy; David Waterhouse, Oncology Hematology Care (OHC)/US Oncology, Cincinnati, OH; Fabrice Barlesi, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Marseille; Jérôme Fayette, Léon Bérard, Lyon, France; Scott Antonia, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Oscar Arrieta, Instituto Nacional De Cancerologia, Mexico City, Mexico; Naiyer Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; William J. Geese, Ang Li, Anne Blackwood-Chirchir, and Diane Healey, Bristol-Myers Squibb, Princeton, NJ; and Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.3062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075826PMC
December 2017

Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?

Transl Lung Cancer Res 2017 Dec;6(Suppl 1):S78-S83

Medical Oncology Department, Vall d'Hebron Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://tlcr.amegroups.com/article/view/16551/14116
Publisher Site
http://dx.doi.org/10.21037/tlcr.2017.10.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750169PMC
December 2017

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

J Clin Oncol 2017 Aug 13;35(24):2781-2789. Epub 2017 Jun 13.

Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne; Martin Früh, Kantonsspital St Gallen, St Gallen, Switzerland; Scott Gettinger, Yale Cancer Center, New Haven, CT; Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, TN; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Daniel Christoph, Universitätsklinikum Essen, and the Ruhrlandklinik, Universität Duisburg-Essen, Essen; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; Chee Keong Toh, National Cancer Centre, Singapore, Singapore; Naiyer A. Rizvi and Jamie E. Chaft, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Weill Cornell Medical College, New York, NY; Enric Carcereny Costa, Catalan Institute of Oncology Badalona, Badalona; Luis Paz-Ares, Hospital Universitario Doce de Octubre & IIS i+12, CNIO, Ciberonc and Universidad Complutense, Madrid; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Jyoti D. Patel, University of Chicago, Chicago, IL; Laura Q.M. Chow, University of Washington, Seattle, WA; Marianna Koczywas, City of Hope, Duarte; Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, and Alan Sandler, Genentech, South San Francisco, CA; Cheryl Ho, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia; Jeffrey Rothenstein, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa; Frances A. Shepherd, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada; Michel van den Heuvel, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; and Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.9476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562171PMC
August 2017

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

N Engl J Med 2017 06;376(25):2415-2426

From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany; Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain; H. Lee Moffitt Cancer Center, Tampa, FL (B.C.); Vanderbilt University Medical Center, Nashville (L. Horn); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands; Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Baptist Health Lexington, Lexington, KY (F.B.); Duke University, Durham, NC (N.R.); Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania; Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.); Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.); Santa Maria Hospital, Terni, Italy (E.M.); Hollings Cancer Center, Charleston, SC (J.M.W.); Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.); and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487310PMC
June 2017

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

J Clin Oncol 2017 Apr 21;35(12):1288-1296. Epub 2017 Feb 21.

James Chih-Hsin Yang and Chia-Chi Lin, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China; Myung-Ju Ahn, Sungkyunkwan University; Dong-Wan Kim, Seoul National University Hospital; Sang-We Kim, Asan Medical Center, Seoul; Joo-Hang Kim, CHA University, Gyeonggi-do, Republic of Korea; Suresh S. Ramalingam, Emory University School of Medicine, Atlanta, GA; Lecia V. Sequist, Massachusetts General Hospital; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; David Planchard, Institut Gustave Roussy, Villejuif, France; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Fiona Blackhall, The Christie Hospital; University of Manchester, Manchester; Helen Mann and Serban Ghiorghiu, AstraZeneca, Cambridge; Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom; Daniel Haggstrom, Carolinas Healthcare System, Charlotte, NC; Kiyotaka Yoh, National Cancer Center Hospital East, Kashiwa, Chiba; Tomonori Hirashima, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan; Silvia Novello, University of Turin, Turin, Italy; and Kathryn Gold, University of California San Diego Moores Cancer Center, San Diego, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.3223
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.3223DOI Listing
April 2017

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Cancer Treat Rev 2017 Apr 30;55:181-189. Epub 2017 Mar 30.

University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.03.006DOI Listing
April 2017

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

J Clin Oncol 2016 11;34(31):3740-3748

Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf; Michael Thomas, Translational Lung Research Center Heidelberg, Thoraxklinik im Universitätsklinikum Heidelberg, Heidelberg, Germany; Alexander Luft, Leningrad Regional Clinical Hospital, Leningrad, Russia; Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy w Otwocku, Otwocku, Poland; Libor Havel, Hospital Na Bulovce, Prague, Czech Republic; Sang-We Kim, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea; Wallace Akerley, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Maria Catherine Pietanza, Memorial Sloan Kettering Cancer Center, New York, NY; Kathryn Gold, University of Texas MD Anderson Cancer Center, Houston, TX; Leora Horn, Vanderbilt-Ingram Cancer Center; David Spigel, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Anne Pieters, Teresa Kong Sanchez, and Justin Fairchild, Bristol-Myers Squibb, Princeton, NJ; Yi-long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong, People's Republic of China; Christoph Zielinski, Medical University of Vienna, Vienna, Austria; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Joachim Aerts, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Kazuhiko Nakagawa, Kinki University Hospital, Osaka, Japan; and Paul Lorigan, the Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.6601
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.6601DOI Listing
November 2016

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Authors:
Christian Dittrich Michael Kosty Svetlana Jezdic Doug Pyle Rossana Berardi Jonas Bergh Nagi El-Saghir Jean-Pierre Lotz Pia Österlund Nicholas Pavlidis Gunta Purkalne Ahmad Awada Susana Banerjee Smita Bhatia Jan Bogaerts Jan Buckner Fatima Cardoso Paolo Casali Edward Chu Julia Lee Close Bertrand Coiffier Roisin Connolly Sarah Coupland Luigi De Petris Maria De Santis Elisabeth G E de Vries Don S Dizon Jennifer Duff Linda R Duska Alexandru Eniu Marc Ernstoff Enriqueta Felip Martin F Fey Jill Gilbert Nicolas Girard Andor W J M Glaudemans Priya K Gopalan Axel Grothey Stephen M Hahn Diana Hanna Christian Herold Jørn Herrstedt Krisztian Homicsko Dennie V Jones Lorenz Jost Ulrich Keilholz Saad Khan Alexander Kiss Claus-Henning Köhne Rainer Kunstfeld Heinz-Josef Lenz Stuart Lichtman Lisa Licitra Thomas Lion Saskia Litière Lifang Liu Patrick J Loehrer Merry Jennifer Markham Ben Markman Marius Mayerhoefer Johannes G Meran Olivier Michielin Elizabeth Charlotte Moser Giannis Mountzios Timothy Moynihan Torsten Nielsen Yuichiro Ohe Kjell Öberg Antonio Palumbo Fedro Alessandro Peccatori Michael Pfeilstöcker Chandrajit Raut Scot C Remick Mark Robson Piotr Rutkowski Roberto Salgado Lidia Schapira Eva Schernhammer Martin Schlumberger Hans-Joachim Schmoll Lowell Schnipper Cristiana Sessa Charles L Shapiro Julie Steele Cora N Sternberg Friedrich Stiefel Florian Strasser Roger Stupp Richard Sullivan Josep Tabernero Luzia Travado Marcel Verheij Emile Voest Everett Vokes Jamie Von Roenn Jeffrey S Weber Hans Wildiers Yosef Yarden

ESMO Open 2016 29;1(5):e000097. Epub 2016 Sep 29.

Department of General Medical Oncology , University Hospitals Leuven , Leuven , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070299PMC
September 2016

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

J Clin Oncol 2016 08 28;34(24):2858-65. Epub 2016 Mar 28.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Federico Cappuzzo, Istituto Toscano Tumori, Livorno; Jolanda Paolini, Jennifer Tursi, and Tiziana Usari, Pfizer Oncology, Milan, Italy; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Fiona H. Blackhall, The Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom; Daniel B. Costa, Beth Israel Deaconess Center, Boston, MA; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Keith D. Wilner and Paulina Selaru, Pfizer Oncology, La Jolla, CA; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Kazuhiko Nakagawa, Kinki University, Osaka, Japan; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangzhou, China; and Tony S.K. Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.5888DOI Listing
August 2016

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

J Clin Oncol 2016 08 18;34(24):2866-73. Epub 2016 Jul 18.

Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.5936
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.5936DOI Listing
August 2016

Women in oncology: progress, challenges, and keys to success.

Am Soc Clin Oncol Educ Book 2013 :448-55

From the Johns Hopkins University School of Medicine, Baltimore, MD; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Texas Oncology, US Oncology Network, Dallas, TX; Division of Hematology/Oncology, University of North Carolina School of Medicine, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.448DOI Listing
December 2015

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

N Engl J Med 2015 Oct 27;373(17):1627-39. Epub 2015 Sep 27.

From the Fox Chase Cancer Center, Philadelphia (H.B.); Hospital Universitario Virgen del Rocio, Seville (L.P.-A.), Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.), and Hospital de Madrid, Norte Sanchinarro, Madrid (E.H.) - all in Spain; Vanderbilt-Ingram Cancer Center (L.H.), and Sarah Cannon Research Institute and Tennessee Oncology (D.R.S.) - both in Nashville; Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) and Robert-Bosch-Krankenhaus Stuttgart, Gerlingen (M.K.) - both in Germany; Duke University Medical Center, Durham, NC (N.E.R.); University of Washington, Seattle (L.Q.C.); University of Chicago Medicine and Biological Sciences, Chicago (E.E.V.); Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.), Centre Léon Bérard, Lyon (J.F.), and Centre Hospitalier Universitaire de Rennes, Rennes (H.L.) - all in France; Instituto Nacional de Cancerologia, Mexico City (O.A.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Forlì-Cesena (M.A.B.), and Ospedale di Perugia, Perugia (L.C.) - both in Italy; N.N. Blokhin Russian Cancer Research Center, Moscow (E.P.); University of Texas Southwestern Medical Center, Dallas (D.E.G.); Yale Comprehensive Cancer Center, New Haven, CT (S.N.G.); Memorial Sloan Kettering Cancer Center, New York (C.M.R., N.R.); University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (S.J.A.); Bristol-Myers Squibb, Princeton, NJ (C.D., C.T.H., F.G.F.); and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.R.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1507643DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705936PMC
October 2015

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1689-99

From the Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston (P.A.J.); National Taiwan University and National Taiwan University Hospital (J.C.-H.Y.) and Cheng Kung University Hospital (W.-C.S.) - both in Taipei, Taiwan; Seoul National University Hospital (D.-W.K.), Samsung Medical Center (M.-J.A.), Asan Medical Center (S.-W.K.), and Yonsei Cancer Center, Yonsei University Health System (J.-H.K.) - all in Seoul, South Korea; Institut Gustave Roussy, Villejuif, France (D.P.); National Cancer Center Hospital, Tokyo (Y.O.); Winship Cancer Institute of Emory University, Atlanta (S.S.R.); Vanderbilt Ingram Cancer Center, Nashville (L.H.); Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC (D.H.); Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.); and AstraZeneca, Macclesfield (P.F., M.C., K.H.B., P.A.D., S.G.), and University of Manchester, Christie Hospital, Manchester (M.R.) - both in the United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411817DOI Listing
April 2015

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

N Engl J Med 2014 Dec;371(23):2167-77

From Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); State Key Laboratory of South China, Hong Kong Cancer Institute, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin (T. Mok), and Guangdong Lung Cancer Institute, Guangzhou (Y.-L.W.) - both in China; Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Kinki University, Osaka, Japan (K.N.); Florida Hospital Cancer Institute, Orlando (T. Mekhail); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (E.F.); Istituto Toscano Tumori, Livorno (F.C.), and Pfizer Oncology, Milan (J.P., T.U., J.T.) - both in Italy; Pfizer Oncology (S.I.) and Pfizer Global Innovative Pharma Business (A.R.) - both in New York; Pfizer Oncology, La Jolla, CA (K.D.W.); and the Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom (F.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1408440DOI Listing
December 2014

Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.

J Thorac Oncol 2014 Nov;9(11):1675-84

*Centre Hospitalier Universitaire de Vaud, Lausanne, Switzerland; †Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; ‡Frontier Science Foundation-Hellas & University of Athens, Athens, Greece; §Aberdeen Royal Infirmary, Aberdeen, United Kingdom; ‖Institute for Pathology, University Hospital Basel, Basel, Switzerland; ¶Department of Oncology, University Hospital, Aarhus, Denmark; #Department of Medical Oncology, St. James's Hospital, Dublin, Ireland; **Medical University of Gdansk, Gdansk, Poland; ††University Hospital KU Leuven, Leuven, Belgium; ‡‡Vall d'Hebron University Hospital, Barcelona, Spain; §§Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; ‖‖Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; ¶¶VU University Medical Center, Amsterdam, Netherlands; ##Maastricht University Medical Centre, Maastricht, Netherlands; ***Manchester University and The Christie National Health Services Foundation Trust, Manchester, United Kingdom; †††Netherlands Cancer Institute, Amsterdam, Netherlands; ‡‡‡Department of Medicine, University of Valencia and Department of Medical Oncology, General University Hospital of Valencia, Valencia, Spain; §§§Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; and ‖‖‖Clinic of Oncology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000320DOI Listing
November 2014

Ganitumab for the treatment of small-cell lung cancer.

Expert Opin Investig Drugs 2014 Oct 5;23(10):1423-32. Epub 2014 Sep 5.

Vall d´Hebron University Hospital and Vall d´Hebron Institute of Oncology, Medical Oncology Department , Barcelona , Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2014.951434DOI Listing
October 2014

Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?

Lung Cancer 2014 May 30;84(2):97-100. Epub 2014 Jan 30.

Vall d́Hebron University Hospital, Department of Medical Oncology, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.01.018DOI Listing
May 2014

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

Clin Cancer Res 2014 Apr 3;20(7):2001-10. Epub 2014 Feb 3.

Authors' Affiliations: Pangaea Biotech, Barcelona, Spain; Hospital Sant Pau, Barcelona, Spain; Hospital Vall d'Hebron, Barcelona, Spain; Molecular Oncology Research (MORe) Foundation, Barcelona, Spain; Pivotal, Madrid; Hospital General de Alicante, Alicante, Spain; Catalan Institute of Oncology, Badalona, Barcelona, Spain; Complejo Hospitalario Universitario, La Coruña, Spain; Centre François Baclesse, Caen, France; Drum Tower Hospital, Nanjing, China; Kyushu University, Fukuoka, Japan; Cancer Therapeutics Innovation Group, New York, New York, USA; and Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2233DOI Listing
April 2014

Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

J Thorac Oncol 2014 Mar;9(3):316-23

*Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts; †Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; ‡Translational Medicine, Exelixis, Inc., South San Francisco, San Francisco, California; §Translational and Experimental Medicine, Sanofi, Vitry-sur-Seine, France; ‖Center for Thoracic Centers, Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts; ¶Clinical Development Oncology, Sanofi, Cambridge, Massachusetts; #Pharmacokinetic Modeling and Simulation, Sanofi, Cambridge, Massachusetts; **Biostatistics and Programming, Sanofi, Cambridge, Massachusetts; ††Early Drug Development Center, Dana-Farber Cancer Institute, Boston, Massachusetts; ‡‡Department of Medical Oncology, Vall d'ebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153021
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000088DOI Listing
March 2014

Ceritinib in ALK-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Mar;370(13):1189-97

From Massachusetts General Hospital, Boston (A.T.S., J.A.E.); Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Fox Chase Cancer Center, Philadelphia (R.M.); National Cancer Center and Genome Institute of Singapore, Singapore (D.S.W.T.); Vall d'Hebron University, Barcelona (E.F.); University of Washington, Seattle (L.Q.M.C.); University of Colorado, Denver (D.R.C.); University Hospital KU Leuven, Leuven, Belgium (J.V.); Huntsman Cancer Institute, Salt Lake City (S.S.); Istituto Europeo di Oncologia (T.D.P.) and Istituto di Ricovero e Cura a Carattere Scientifico Istituto Clinico Humanitas (A.S.) - both in Milan; Memorial Sloan-Kettering Cancer Center, New York (G.J.R.); Peter MacCallum Cancer Center, Melbourne, VIC, Australia (B.J.S.); Center for Integrated Oncology, University Hospital Cologne, Cologne (J.W.), Thoraxklinik, University of Heidelberg, Translational Lung Research Center Heidelberg, German Center for Lung Research (M.T.), and German Cancer Consortium (M.S.), Heidelberg, and University Duisburg-Essen, Essen (M.S.) - all in Germany; Princess Margaret Cancer Center, Toronto (G.L.); and Novartis Institutes for BioMedical Research, Cambridge, MA (Y.Y.L., M.G., A.L.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1311107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079055PMC
March 2014

Strategies for improving outcomes in NSCLC: a look to the future.

Lung Cancer 2013 Dec 8;82(3):375-82. Epub 2013 Sep 8.

Department of Oncology, University Hospital Zurich, Zurich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.08.025DOI Listing
December 2013

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.

Sci Rep 2013 Dec 18;3:3544. Epub 2013 Dec 18.

1] Breast Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain [2] Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep03544DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506566PMC
December 2013

An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.

J Thorac Oncol 2013 Dec;8(12):1529-37

*Department of Clinical and Biological Sciences, University of Turin, Orbassano, Torino, Italy; †Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; ‡Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France; §Asklepios Clinic, Asklepios Fachkliniken München-Gauting, Gauting, Germany; ‖Department of Oncology, Herlev Hospital, Onkologisk afdeling, Herlev, Denmark; ¶Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany; #Department of Respiratory Medicine, Centre Hospitalier Universitaire de Liege, Liege, Belgium; **Department of Respiratory Medicine, Hopital Saint-Antoine, Paris Cedex, France; ††Department of Medical Oncology, Hospital de Mataro, Mataro, Spain; and ‡‡Oncology Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina; Collegeville, Philadelphia, Pennsylvania; and Uxbridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000005DOI Listing
December 2013

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Cancer Discov 2013 Nov 15;3(11):1238-44. Epub 2013 Aug 15.

1Vall d'Hebron Institut d'Oncologia; 2Vall d'Hebron Institut de Recerca; 3Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona; 4Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain; and 5Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0132DOI Listing
November 2013

Neoadjuvant chemotherapy in early-stage non-small cell lung cancer.

Transl Lung Cancer Res 2013 Oct;2(5):398-402

Oncology Department, Valld'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.tlcr.org/article/view/1613
Publisher Site
http://dx.doi.org/10.3978/j.issn.2218-6751.2013.10.07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367730PMC
October 2013